Difference between revisions of "Concluding Remarks section from DOI: 10.3390/pathogens9020148 (Q7907)"
Jump to navigation
Jump to search
(Removed claim: has part (P22): Item:Q7902) |
(Created claim: follows (P40): Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 (Q7906)) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / followed by | |||
| + | |||
| Property / followed by: Table 1 - Advantages and disadvantages of different therapeutic protein production platforms (From DOI: 10.3390/pathogens9020148) / rank | |||
| + | Normal rank | ||
| Property / IMRaD(C) Section | |||
| + | |||
| Property / IMRaD(C) Section: Conclusion / rank | |||
| + | Normal rank | ||
| Property / follows | |||
| + | |||
| Property / follows: Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 / rank | |||
| + | Normal rank | ||
Latest revision as of 20:07, 13 April 2020
Main section in the article "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Concluding Remarks section from DOI: 10.3390/pathogens9020148
|
Main section in the article "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148
|
